DEA Moves to Reclassify Marijuana to Schedule III, Amid Mixed Reactions
The DEA's decision to reclassify marijuana from Schedule I to Schedule III has sparked varied responses, highlighting the complexity of drug policy reform.
- The DEA plans to reclassify marijuana as a Schedule III drug, which includes substances like ketamine and anabolic steroids.
- This move is seen as a significant shift in federal drug policy but does not legalize marijuana for recreational use.
- Critics argue the change fails to address major issues such as federal-state legal conflicts and does not decriminalize marijuana.
- The reclassification could reduce financial burdens on legal cannabis businesses by allowing them to deduct standard business expenses.
- Advocates and industry leaders express a mix of optimism and disappointment, pushing for more comprehensive cannabis reform.
Denver Gazette 
GZERO Media 
Benzinga 
Rolling Stone 
Reason.com 
MSNBC 
Washington Examiner Benzinga 
Newsweek 
The Daily Signal 
Star Tribune 
USA TODAY 
Semafor Benzinga Newsweek 
Crooks and Liars 
Los Angeles Times Los Angeles Times 
The Bulwark 
Chicago Tribune 
The Japan Times 
Forbes 
Associated Press 
Boston Globe 
Al Jazeera 
SFist 
Chicago Sun Times 
ScienceAlert 
The Denver Post Chicago Tribune 
Le Monde 
HuffPost 
The Hill 
NJ.com Benzinga 
Deutsche Welle Associated Press 
The Daily Wire The Hill 
VERIFY Forbes 
The Post Millennial 
UPI 
Gizmodo 
Ars Technica 
NBC News 
The Philadelphia Inquirer 
CNA Forbes 
South China Morning Post Benzinga 
Voice of America (VOA News) Reason.com 
The Daily Beast Forbes Newsweek Washington Examiner 
Common Dreams 
Investopedia 
Markets Insider 
The Daily Caller Benzinga 
CNBC 
ABC News 
Sky News Forbes 
New York Daily News Forbes 
Fox News 
CNN 
The Oregonian 
Washington Post USA TODAY 
New York Post 
Stat News NBC News HuffPost 
Financial Post ABC News 
One America News Network 
Salon 
Mother Jones 
Breitbart 
